Clinical trials
Cannabis Use Disorder, Moderate clinical trials
Below are recruiting cannabis use disorder, moderate clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06136195RecruitingPhase 1
Mavoglurant for alcohol craving in heavy drinkers
This trial tests whether a medication called mavoglurant can reduce alcohol cravings and drinking in people who are heavy drinkers with alcohol use disorder and are not looking for treatment.
New Haven, ConnecticutAges 21–50 - NCT06513819RecruitingPhase 1
HIV and Alcohol Study for People on Multiple Medications
This study looks at how alcohol use affects people with HIV who take multiple medications, including certain brain or nerve drugs. It aims to find safer ways to manage their health.
West Haven, ConnecticutAges 50 years+ - NCT06617312RecruitingPhase 2
Cytisinicline and brain response to smoking cues
This study tests how a medicine called cytisinicline (similar to a plant-based stop-smoking aid) affects brain activity when you see or think about smoking. It may help researchers understand how the medicine works, even if you aren't ready to quit right now.
Los Angeles, CaliforniaAges 18–65 - NCT06793488RecruitingEarly Phase 1
Anxiety and alcohol use disorder treatment study
This study tests whether a medication called disulfiram (Antabuse) can help people with alcohol use disorder (AUD) feel less anxious when they stop drinking. Researchers will also use brain scans (MRI) to look at how the brain changes during early abstinence.
New York, New YorkAges 21–55 - NCT06899594RecruitingEarly Phase 1
Psilocybin for quitting methamphetamine
This trial tests whether psilocybin (a psychedelic medicine) can help people quit methamphetamine. You'll receive counseling before, during, and after the drug session, and your progress will be followed for several months.
Shreveport, LouisianaAges 25–65 - NCT07118618RecruitingPhase 2
Probenecid for alcohol cravings and drinking
This study tests if the medication probenecid can help reduce cravings for alcohol and the amount you drink. It is for people who drink heavily and have moderate to severe alcohol use disorder.
Providence, Rhode IslandAges 18 years+ - NCT04043442Enrolling by invitationPhase 2
Brain stimulation study for alcohol use with mild brain injury
This trial tests a type of brain stimulation to help with day-to-day functioning in people who have alcohol use disorder and a history of mild traumatic brain injury. It also uses brain and symptom testing to see who may benefit most and why.
Hines, IllinoisAges 22–65 - NCT06752759RecruitingPhase 3
Ketamine mist for depression
This trial tests if a ketamine mist you breathe in can help treat moderate to severe depression. It is for adults who are not helped enough by other treatments.
Brooklyn, New YorkAges 18–88 - NCT07477990RecruitingPhase 3
Testing a digital device for anxiety treatment
This trial is testing a digital device called Aurora that helps treat moderate to severe anxiety. It compares the device to standard anxiety medications, so you may receive either the device or a pill. The goal is to see if the device can work as well as medication without the side effects.
Mexico City, Mexico CityAges 18–65 - NCT07123467RecruitingPhase 3
Study on CBD and learning for generalized anxiety
This trial tests if adding cannabidiol (CBD) to a learning-based approach helps manage generalized anxiety disorder (GAD). It involves brain scans and taking CBD daily.
Detroit, MichiganAges 18–45 - NCT06991205Recruiting
Web mind-body program for pain and substance use
This trial tests a web-based mind-body program to help people who have ongoing arm or hand pain and also use substances like alcohol or cannabis. It aims to improve resilience and reduce pain without requiring in-person visits.
Boston, MassachusettsAges 18 years+ - NCT04810858Recruiting
Study how chronic marijuana affects brain inflammation in HIV
This study looks at whether ongoing marijuana use changes “brain inflammation” and brain cell injury in people living with HIV. It may help researchers understand potential risks or protective effects and how treatment and brain health interact.
Winston-Salem, North CarolinaAges 25–59 - NCT07199218RecruitingPhase 2
Cannabis oil for autism in children aged 4 to 12
This trial tests a cannabis oil enriched with terpenes (natural compounds that may affect behavior) to see if it helps reduce severe symptoms in children with autism. It compares the oil to a placebo.
Jerusalem, N/A = Not ApplicableAges 4–13
Hear when a new Cannabis Use Disorder, Moderate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cannabis use disorder, moderate?
- Yes. Clin2 currently lists 61 recruiting cannabis use disorder, moderate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cannabis use disorder, moderate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cannabis use disorder, moderate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.